Research ArticleArticle
Open Access
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Philip J. Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F. Wells, Martin Bergman, Dafna D. Gladman, Sven Richter, Lichen Teng, Shauna Jardon and Josef S. Smolen
The Journal of Rheumatology April 2022, jrheum.210906; DOI: https://doi.org/10.3899/jrheum.210906
Philip J. Mease
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Arthur Kavanaugh
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Alexis Ogdie
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Alvin F. Wells
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Martin Bergman
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Dafna D. Gladman
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Sven Richter
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Lichen Teng
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Shauna Jardon
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
Josef S. Smolen
This study was sponsored by Amgen Inc. P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA; A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA; A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA; M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; S. Richter, MD, L. Teng, PhD, S. Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA; J.S. Smolen, MD, Medical University of Vienna, Austria. PJM has received grant/research support from and served as a consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, GSK, Novartis, Pfizer, Sun, and UCB, and has been a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. AK has received grant/research support from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB. AO has received grant/research support from AbbVie, Novartis, and Pfizer, and has served as a consultant to AbbVie, Amgen, BMS, Celgene, Corrona (now CorEvitas, LLC), Eli Lilly, Gilead, Novartis, Pfizer, and UCB. AFW has received grant/research support from AbbVie, Celgene, and Lilly, and has served as a consultant and speaker for AbbVie, Alexion, Amgen, BMS, Celgene, Horizon, Lilly, Novartis, and UCB. MB has served as a speaker for AbbVie, Amgen, Novartis, Pfizer, and Sanofi; has served as a consultant for AbbVie, BMS, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, and Sanofi; and is a stockholder in Johnson & Johnson. DDG has received grant/research support from and/or served as a consultant for AbbVie, Amgen, BMS, Celgene Corporation, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. SR, LT, and SJ are employees of and stockholders in Amgen Inc. JSS has received grant/ research support from AbbVie, AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, and Roche, and has served as a consultant and speaker for AbbVie, Amgen, Astro, Celgene, Celltrion, Eli Lilly, Glaxo, ILTOO, Janssen, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, Sanofi, and UCB. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA. Email: pmease@philipmease.com. Accepted for publication March 29, 2022.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Philip J. Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F. Wells, Martin Bergman, Dafna D. Gladman, Sven Richter, Lichen Teng, Shauna Jardon, Josef S. Smolen
The Journal of Rheumatology Apr 2022, jrheum.210906; DOI: 10.3899/jrheum.210906
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Philip J. Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F. Wells, Martin Bergman, Dafna D. Gladman, Sven Richter, Lichen Teng, Shauna Jardon, Josef S. Smolen
The Journal of Rheumatology Apr 2022, jrheum.210906; DOI: 10.3899/jrheum.210906